Ayala Pharmaceuticals (ADXS) Competitors $0.03 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends ADXS vs. ONCT, XCUR, BFRI, GHSI, PCSA, ATNF, SNPX, FRTX, MYMD, and KTTAShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Oncternal Therapeutics (ONCT), Exicure (XCUR), Biofrontera (BFRI), Guardion Health Sciences (GHSI), Processa Pharmaceuticals (PCSA), 180 Life Sciences (ATNF), Synaptogenix (SNPX), Fresh Tracks Therapeutics (FRTX), MyMD Pharmaceuticals (MYMD), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Oncternal Therapeutics Exicure Biofrontera Guardion Health Sciences Processa Pharmaceuticals 180 Life Sciences Synaptogenix Fresh Tracks Therapeutics MyMD Pharmaceuticals Pasithea Therapeutics Ayala Pharmaceuticals (NASDAQ:ADXS) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability. Which has more volatility & risk, ADXS or ONCT? Ayala Pharmaceuticals has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Does the MarketBeat Community prefer ADXS or ONCT? Oncternal Therapeutics received 32 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 26.89% of users gave Oncternal Therapeutics an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAyala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes60100.00% Oncternal TherapeuticsOutperform Votes3226.89% Underperform Votes8773.11% Do institutionals & insiders have more ownership in ADXS or ONCT? 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer ADXS or ONCT? Oncternal Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 1,251.35%. Given Oncternal Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oncternal Therapeutics is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Oncternal Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is ADXS or ONCT more profitable? Ayala Pharmaceuticals has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,948.70%. Ayala Pharmaceuticals' return on equity of 0.00% beat Oncternal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A Oncternal Therapeutics -1,948.70%-136.10%-108.25% Which has higher valuation & earnings, ADXS or ONCT? Oncternal Therapeutics has higher revenue and earnings than Ayala Pharmaceuticals. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$10K115.31-$48.07M-$7.980.00Oncternal Therapeutics$790K5.55-$39.48M-$12.23-0.12 Does the media refer more to ADXS or ONCT? In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Oncternal Therapeutics. Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Oncternal Therapeutics'average media sentiment score. Company Overall Sentiment Ayala Pharmaceuticals Neutral Oncternal Therapeutics Neutral SummaryOncternal Therapeutics beats Ayala Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad TradingTips10 EV Stocks to Buy Right NowEV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.Click here to view all 10 stocks right away. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15M$6.75B$5.04B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio0.0012.17130.2316.67Price / Sales115.31270.431,720.2276.26Price / CashN/A46.0936.9133.54Price / Book-0.015.284.604.98Net Income-$48.07M$151.33M$114.94M$224.26M7 Day PerformanceN/A0.30%0.14%1.65%1 Month PerformanceN/A14.88%10.15%6.92%1 Year PerformanceN/A36.87%33.87%26.46% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03flatN/A-97.0%$1.15M$10,000.000.0020Analyst ForecastNews CoverageONCTOncternal Therapeutics2.4467 of 5 stars$1.53+6.3%$20.00+1,207.2%-79.2%$4.53M$790,000.00-0.1330Analyst ForecastHigh Trading VolumeXCURExicure2.3529 of 5 stars$2.58+7.1%N/A+401.6%$4.46M$28.83M-0.5750BFRIBiofrontera2.3851 of 5 stars$0.88-1.1%$7.00+699.1%-75.5%$4.46M$35.24M-0.1570Gap DownGHSIGuardion Health Sciences1.6271 of 5 stars$3.29flatN/A-47.6%$4.44M$12.23M0.6810Upcoming EarningsGap DownPCSAProcessa Pharmaceuticals2.399 of 5 stars$1.35flat$6.00+344.4%-83.5%$4.40MN/A-0.3420Negative NewsATNF180 Life SciencesN/A$4.43+4.7%N/A-54.0%$4.34MN/A0.007Gap UpSNPXSynaptogenix1.7233 of 5 stars$3.18-1.2%$14.00+340.3%-60.8%$4.33MN/A0.004Gap DownFRTXFresh Tracks TherapeuticsN/A$0.72flatN/A-18.9%$4.30M$8.01M-0.5120MYMDMyMD PharmaceuticalsN/A$1.76+4.8%N/A-88.6%$4.17MN/A0.009Gap UpKTTAPasithea TherapeuticsN/A$3.92+6.2%N/A-47.2%$4.09M$20,000.000.003Upcoming Earnings Related Companies and Tools Related Companies Oncternal Therapeutics Alternatives Exicure Alternatives Biofrontera Alternatives Guardion Health Sciences Alternatives Processa Pharmaceuticals Alternatives 180 Life Sciences Alternatives Synaptogenix Alternatives Fresh Tracks Therapeutics Alternatives MyMD Pharmaceuticals Alternatives Pasithea Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADXS) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
